Board of Directors
Eugen Steiner
Born: 1954
Other assignments: Chairman of the board of Empros Pharma AB. Board member of Inbox Capital AB and Stockholm School of Entrepreneurship. Member of Royal Swedish Academy of Engineering (IVA) and deputy chairman of its Division X, Biotechnology.
Education: Karolinska Institutet (M.D., Ph.D. in Clinical Pharmacology).
Experience and prior assignments: CEO or acting chairman of the board in several life science companies in Sweden, Norway, Iceland, the UK and the US for more than 35 years.
Board member since: 2017 (Chairman of the Board since 2023)
Committee membership: Remuneration Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 89,000 Class B shares
Cecilia Edström
Born: 1966
Other assignments: Founder and CEO, ceed konsult AB. Board member of Flerie AB and A3P Biomedical AB. Advisory Board Member, European Patient Safety Foundation (EUPSF). Chairman of the board of Perspetivo AB.
Education: Master of Business Administration, Stockholm School of Economics, Sweden.
Experience and prior assignments: More than 30 years of experience in various industries, including life science. Executive roles including CEO and CFO at Bactiguard, member of management groups of TeliaSonera and Scania (and corporate finance at SEB).
Board member since: 2023
Committee membership: Chairman of the Audit committee.
Independent in relation to the company, its executive management and the major shareholders of the company.
Total holdings* in BioArctic: 6,500 Class B shares.
Anna-Lena Engwall
Born: 1971
Other assignments: Global Commercial Vice President Cardiovascular ar Strangeness, based in Cambridge, UK.
Education: B. Sc in Nursing, Karolinska Institutet and DIHM, Marketing and Business.
Experience and prior assignments: More than 25 years of experience in the life science and pharmaceutical industries, with executive roles in commercialization, marketing, and drug and business development, and during her career has held several positions at Shire and Novartis, both in Sweden and internationally.
Board member since: 2024
Committee membership: Audit Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 448 Class B-shares.
Pär Gellerfors
Born: 1947
Other assignments: Founder and board member of Ackelsta AB, LPB Sweden AB.
Education: Bachelor degree in chemistry; PhD in chemistry; Associate Professor of Biochemistry. All at Stockholm University, Sweden.
Experience and prior assignments: Founder of BioArctic in 2003, CEO of the company until 2013. CEO and board member of Swenora Biotech AB; founder and research director at Zymenex AS; founder and board member of LPB Sweden Holding AB; board member of Sigrid AB. Founder and CEO of MPG Medical AB.
Committee membership: Remuneration Committee
Board member since: 2003
Independent in relation to the company and company management. Not independent in relation to major shareholders in the company.
Total holdings* in BioArctic: 5,759,998 Class A-shares through Ackelsta AB. 12,143,201 Class B-shares through Ackelsta AB.
Lars Lannfelt
Born: 1949
Other assignments: Founder and board member of Demban AB and LPB Sweden AB.
Education: Medical degree (specialist in psychiatry) and doctoral thesis at Karolinska Institutet, Stockholm, Sweden; Associate Professor of Neurogenetics at Karolinska Institutet, specialist in geriatrics.
Experience and prior assignments: More than 35 years of experience in research into Alzheimer’s disease and other neurodegenerative diseases. Professor of Geriatrics at Uppsala University; member of the Royal Swedish Academy of Sciences. Founder of BioArctic in 2003, Chairman of the Board of BioArctic until 2017 and a number of assignments and roles in the company.
Board member since: 2003
Not independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 8,639,998 Class A-shares through Demban AB. 19,685,052 Class B-shares through Demban AB. Owns 7,000 Class B-shares privately.
Lotta Ljungqvist
Born: 1961
Other assignments: Board member of Genovis AB, NorthXBiologics AB and BioLamina AB.
Education: Degree in biochemistry from KTH Royal Institute of Technology in Stockholm, Sweden. Doctorate in biochemical technology.
Experience and prior assignments: CEO of Testa Center, Cytiva (formerly GE Healthcare Life Sciences). Executive roles as CEO, head of business area, head of research and project manager for biopharma projects at GE Healthcare Life Sciences, Biovitrum and Pharmacia. Board member of several life science companies.
Board member since: 2021
Committee membership: Chairman of the Remuneration Committee.
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 3,159 class B-shares
Mikael Smedeby
Born: 1968
Other assignments: Lawyer and partner at Advokatfirman Lindahl. Chairman of the board of Coeli Holding AB (including subsidiaries), Sallengruppen AB (including subsidiaries) and Uppsala Akademiförvaltning. Board member of Sirius Fotboll and Mikael Smedeby Advokat AB.
Education: Master of Laws, Uppsala University, Sweden. Reserve officer training at the Swedish Infantry Officers’ College and the Swedish Infantry Combat School.
Experience and prior assignments: Special experience in corporate law, mergers and acquisitions, financing and licensing. Held executive positions at Advokatfirman Lindahl 2010–2019, including Managing Partner and chairman of the board. Member of the Board of Directors of BioArctic, 2014–2017.
Board member since: 2018
Committee membership: Audit Committee
Independent in relation to the company and management, and to major shareholders in the company.
Total holdings* in BioArctic: 4,422 Class B-shares
*Includes holdings by self, closely associated persons, controlled companies or in capital insurance accounts.